Clinical trial preview — no account needed

A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Transcranial Magnetic Stimulation for Treatment Resistant Depression: The MIND1 Trial

ClinicalTrials.gov · November 12, 2025

Preview

Major depressive disorder (MDD) is a significant public health problem and leading cause of worldwide disability. Treatment resistance is common in MDD, however, for these individuals, targeted noninvasive brain stimulation is an alternative.

The complete summary, “why it matters” analysis and the original source link are available to members.

Phase 2TMSDepressionNeurostimulation